Melanie Mcginlay

发表

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction

K. Witte, M. McGinlay, S. Straw, 2021, Open Heart.

Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction

Thomas A. Slater, M. Kearney, R. Cubbon, 2022, Clinical Research in Cardiology.

Effect of disease‐modifying agents and their association with mortality in multi‐morbid patients with heart failure with reduced ejection fraction

Samuel D. Relton, M. Kearney, S. Relton, 2020, ESC heart failure.

We don't talk to patients about their prognosis, but is any of this surprising?

J. Gierula, K. Witte, M. McGinlay, 2021, Journal of cardiac failure.

Suboptimal Dosing of β-Blockers in Chronic Heart Failure

Samuel D. Relton, M. Kearney, S. Relton, 2021, The Journal of cardiovascular nursing.

Prioritizing symptom management in the treatment of chronic heart failure

M. Kearney, R. Cubbon, J. Gierula, 2020, ESC heart failure.

Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial

M. Kearney, R. Cubbon, J. Gierula, 2021, PloS one.

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure

Thomas A. Slater, M. Kearney, K. Birch, 2022, ESC heart failure.

Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure

M. Kearney, R. Cubbon, J. Gierula, 2021, Journal of cardiovascular medicine.

Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data

Samuel D. Relton, Thomas A. Slater, M. Kearney, 2020, BMC Palliative Care.